Improving chemotherapy outcome in early breast cancer

Affiliations

¹ Department of Breast & Endocrine Surgery, Lyell McEwin and Modbury Hospitals, Northern Adelaide Local Health Network, South Australia, Australia.
² Department of Medical Oncology, Lyell McEwin Hospital, University of Adelaide, Adelaide, South Australia, Australia.

Editorial

Anurag Gupta et al. Gland Surg. 2019 Oct.

. 2019 Oct;8(5):585-587.

doi: 10.21037/gs.2019.08.04.

¹ Department of Breast & Endocrine Surgery, Lyell McEwin and Modbury Hospitals, Northern Adelaide Local Health Network, South Australia, Australia.
² Department of Medical Oncology, Lyell McEwin Hospital, University of Adelaide, Adelaide, South Australia, Australia.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8. Lancet. 2019. PMID: 30739743 Free PMC article.

1. Cossetti RJ, Tyldesley SK, Speers CH, et al. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J Clin Oncol 2015;33:65-73. 10.1200/JCO.2014.57.2461 - DOI - PubMed
1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019;393:1440-52. 10.1016/S0140-6736(18)33137-4 - DOI - PMC - PubMed
1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44. 10.1016/S0140-6736(11)61625-5 - DOI - PMC - PubMed
1. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83. 10.1200/JCO.2003.02.063 - DOI - PubMed
1. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205-11. 10.1093/jnci/90.16.1205 - DOI - PubMed